… -oxLDL IgM antibodies due to mimicry of anti-phosphorylcholine (present in the cell wall of
S. … antibodies and acute coronary syndrome, suggesting an untoward role of this antibody in …

… have been no reports on cardiovascular outcomes. Belimumab is the … roles of antibody-dependent
complement activation in CVD, … Namely, antibodies against phosphorylcholine on the …

… antibodies for therapy which can be applied for CVD. As such, we would also review … CVD
outcomes. A brief overview of each target would be provided to correlate the need of antibody …

… In addition to its high affinity for phosphocholine in the … Immunonephelometry operates on
the formation of antigen-antibody … experience improved cardiovascular outcomes, regardless …

… improve outcomes in atherosclerotic cardiovascular disease. … -interleukin-1 beta monoclonal
antibody, canakinumab, and … of natural anti-phosphorylcholine antibodies of the IgM …

… in lupus patients given anifrolumab, a human monoclonal antibody to type I interferon receptor
subunit 1. In this placebo-controlled study, inhibition of type I IFN activity by this antibody …

… risk in patients with elevated high-sensitivity PCR and very low LDL cholesterol concentrations
and, ultimately, whether treatment with an anti-IL-1β monoclonal antibody would be …

… A detection monoclonal antibody E06 was subsequently added, which binds to the
phosphocholine (… The impact of traditional cardiovascular risk factors on cardiovascular outcomes …

… On the other hand, their therapeutic targeting improved cardiovascular outcomes [6]. While …
, the detection monoclonal antibody E06 was added, which binds to the phosphocholine (PC) …

… been used to identify the phosphocholine (PC) headgroup in … -apo(a) antibody as capture
antibody but it has been studied … /apoB with CVD outcomes was independent of most CVD risk …